ID: ALA4438514

Max Phase: Preclinical

Molecular Formula: C26H25FN8O

Molecular Weight: 484.54

Molecule Type: Unknown

Representations

Canonical SMILES:  CNCCNC(=O)c1c(-c2ccccc2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12

Standard InChI:  InChI=1S/C26H25FN8O/c1-15(34-25-19(13-28)24(29)32-14-33-25)23-21(16-6-4-3-5-7-16)22(26(36)31-11-10-30-2)18-12-17(27)8-9-20(18)35-23/h3-9,12,14-15,30H,10-11H2,1-2H3,(H,31,36)(H3,29,32,33,34)/t15-/m0/s1

Standard InChI Key:  YMHUMUWJNIVIFZ-HNNXBMFYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 484.54

Molecular Weight (Monoisotopic): 484.2135

AlogP: 3.41

#Rotatable Bonds: 8

Polar Surface Area: 141.64

Molecular Species: BASE

HBA: 8

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 9.58

CX LogP: 2.77

CX LogD: 0.63

Aromatic Rings: 4

Heavy Atoms: 36

QED Weighted: 0.28

Np Likeness Score: -0.98

References

1. Gonzalez-Lopez de Turiso F, Hao X, Shin Y, Bui M, Campuzano ID, Cardozo M, Dunn MC, Duquette J, Fisher B, Foti RS, Henne K, He X, Hu YL, Kelly RC, Johnson MG, Lucas BS, McCarter J, McGee LR, Medina JC, Metz D, San Miguel T, Mohn D, Tran T, Vissinga C, Wannberg S, Whittington DA, Whoriskey J, Yu G, Zalameda L, Zhang X, Cushing TD..  (2016)  Discovery and in Vivo Evaluation of the Potent and Selective PI3Kδ Inhibitors 2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-6-fluoro-N-methyl-3-(2-pyridinyl)-4-quinolinecarboxamide (AM-0687) and 2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-5-fluoro-N-methyl-3-(2-pyridinyl)-4-quinolinecarboxamide (AM-1430).,  59  (15): [PMID:27411843] [10.1021/acs.jmedchem.6b00827]

Source

Source(1):

• Scientific Literature